Lifespan Vision Ventures Invests In Nanotics

LifeSpan Vision Ventures, an investment firm dedicated to longevity biotech, today announced an investment in NaNotics LLC. This preclinical-stage biopharmaceutical company is developing NaNotsTM, novel subtractive nanoparticles that treat disease by capturing and clearing pathogenic molecules from blood. NaNotsTM differ from traditional drug therapies in their ability to deplete soluble targets without interacting with the membrane forms of the same target, a feat that is typically beyond the reach of conventional drugs.